{"groups":[{"description":"A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia. This is a multicenter(16 sites in the USA), open-label, monotherapy, long-term extension study designed to evaluate the long-term (\\> 6 months) safety and tolerability of a fixed daily dosing regimen of ibrutinib. Ibrutinib was supplied as 140 mg or 40 mg capsules for oral administration. Subjects were to receive daily administration of a fixed dose of ibrutinib at the same dose level as in the parent study (up to 840 mg).","id":"FG000","title":"A LONG-TERM SAFETY STUDY OF BRUTON'S TYROSINE KINASE (BTK) INH"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"199"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"106"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"93"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"This study was open to subjects from prior ibrutinib studies who met eligibility criteria for rollover from their parent study and wanted to continue receiving study drug.","recruitmentDetails":"27 July 2010 (the first Patient enrolled) to 31 March 2016 (the Last patient enrolled), Study was approved on June 2010."}